acetic acid-(4-methyl-hexyl ester) | 91367-59-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: acetic acid-(4-methyl-hexyl ester)
• 英文别名: Essigsaeure-(4-methyl-hexylester)；1-Hexanol, 4-methyl-, acetate；4-methylhexyl acetate
• CAS: 91367-59-8
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: CRMWYQVLRHKJMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲基-1-己醇 、 乙酰氯 生成 acetic acid-(4-methyl-hexyl ester)
  参考文献：
  名称：

  Dewael; Weckering, Bulletin des Societes Chimiques Belges, 1924, vol. 33, p. 504

  摘要：

  DOI：

文献信息

• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：HONIGBERG Lee

  公开号：US20120283276A1

  公开（公告）日：2012-11-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文揭示了能够与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。揭示了制备这些化合物的方法。还揭示了包括这些化合物的药物组合物。揭示了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫疾病或状况，异体免疫疾病或状况，癌症，包括淋巴瘤，以及炎症性疾病或状况。
• AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0661271A1

  公开（公告）日：1995-07-05

  An azepine derivative represented by general formula (1) or a nontoxic salt thereof, a process for producing the same, and a therapeutic agent containing the same as the active ingredient for treating diseases related to σ-receptor, wherein R represents a group represented by general formula (2) (wherein R¹ represents hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen or optionally substituted phenyl, and n represents 0 or 1), C₅-C₈ cycloalkyl which may be substituted by lower alkyl, norbornyl, bicyclo[3.3.1]nonyl, naphthyl, 1,3-benzodioxolyl, pyridyl or thienyl; m represents an integer of 0 to 4; and C* represents an asymmetric carbon atom. The compound (1) and nontoxic salt thereof have a high affinity for σ-receptor but scarcely any affinity for other receptors, thus being utilized for treating diseases related to σ-receptor, such as schizophrenia.

  通式(1)代表的氮杂环庚烷衍生物或其无毒盐，生产该衍生物的工艺，以及含有该衍生物作为活性成分的治疗剂，用于治疗与σ-受体有关的疾病、其中 R 代表通式 (2) 所代表的基团（其中 R¹ 代表氢、低级烷基、低级烷氧基、羟基、卤素或任选取代的苯基，且 n 代表 0 或 1）、可被低级烷基取代的 C₅-C₈ 环烷基、降冰片烷基、双环[3.3.1]壬基、萘基、1,3-苯并二恶茂基、吡啶基或噻吩基；m 代表 0 至 4 的整数；C* 代表不对称碳原子。化合物(1)及其无毒盐对σ受体有很高的亲和力，但对其他受体几乎没有亲和力，因此可用于治疗与σ受体有关的疾病，如精神分裂症。
• US9490480B2
  申请人：——

  公开号：US9490480B2

  公开（公告）日：2016-11-08
• [EN] MOLECULAR PRECURSORS FOR LITHIUM ION BATTERY CATHODE MATERIALS<br/>[FR] PRÉCURSEURS MOLÉCULAIRES POUR MATÉRIAUX DE CATHODE POUR ACCUMULATEURS LITHIUM-ION
  申请人：PRECURSOR ENERGETICS INC

  公开号：WO2014004776A2

  公开（公告）日：2014-01-03

  Lithium-cobalt, lithium-manganese and lithium-nickel molecular precursor compounds, compositions and processes for making cathodes for lithium ion batteries. The molecular precursor compounds are soluble and provide processes to make stoichiometric cathode materials with solution-based processes. The cathode material can be, for example, a lithium cobalt oxide, a lithium cobalt phosphate, a lithium cobalt silicate, a lithium manganese oxide, a lithium manganese phosphate, a lithium manganese silicate, a lithium nickel oxide, a lithium nickel phosphate, or a lithium nickel silicate. Cathodes can be made as bulk material in a solid form or in solution, or in various forms including thin films.
• [EN] MOLECULAR PRECURSORS FOR SYNTHESIS OF LITHIUM-IRON-CONTAINING CATHODE MATERIALS<br/>[FR] PRÉCURSEURS MOLÉCULAIRES POUR LA SYNTHÈSE DE MATÉRIAUX DE CATHODE CONTENANT DU LITHIUM- FER
  申请人：PRECURSOR ENERGETICS INC

  公开号：WO2014004789A2

  公开（公告）日：2014-01-03

  Lithium-iron molecular precursor compounds, compositions and processes for making a cathode for lithium ion batteries. The molecular precursor compounds are soluble and provide processes to make stoichiometric cathode materials with solution-based processes. The cathode material can be, for example, a lithium iron oxide, a lithium iron phosphate, or a lithium iron silicate. Cathodes can be made as bulk material in a solid form or in solution, or in various forms including thin films.